Cizzle Biotechnology Ltd (Cizzle) was identified by Bould Opportunities (Bould) as its preferred target for a reverse takeover. Cizzle is a spin-out from the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. The presence of nodules often detected on chest scans is suspicious, but not usually a sign of lung disease. Therefore, there is high medical need for a simple blood test to be used alongside a positive chest scan that allows early detection of lung cancer and significantly reduces the number of false positives. The company has raised £2.2m to develop its biomarker test through to CE marking.
If you'd like to be introduced to the team at Cizzle Biotechnology/Bould, get in touch.Request a meeting